Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Recombinant new coronavirus vaccine (CHO cell)
BIOLOGICAL
2 trials
Sponsors
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Conditions
COVID-19
Phase 2
Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)
Completed
NCT05109598
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Start: 2021-11-04
End: 2023-04-06
Updated: 2023-04-25
Phase 4
Safety Study of COVID19 Vaccine on the Market
NCT05890521
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Start: 2022-04-02
End: 2023-06-30
Target: 100000
Updated: 2023-06-06
Related Papers
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
2023-02-17
15 citations